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We examined p16 expression in tumors from a population-based sample of laryngeal cancer cases
diagnosed in the U.S. Samples had been previously genotyped for HPV DNA.
Overall, p16 expression was observed in laryngeal tissue from 8 of 101 (7.9%) cases. p16 expression
was observed in 2 of 16 (12.5%) cases previously determined to be HPV DNA positive. The two cases
dually positive for p16 and HPV DNA were non-keratinizing SCC and papillary SCC tumors that were
positive for genotypes 18 and 35/89, respectively. Positivity for p16 and/or HPV DNA was not associated
with 5-year survival (log-rank p value¼0.55). Our ﬁndings support a limited role of HPV in laryngeal
carcinogenesis. p16 is not a reliable surrogate for HPV status in laryngeal cancers and is not a predictor of
laryngeal cancer survival.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Human papillomavirus (HPV) plays an etiologic and prognostic
role in oropharyngeal cancer [1–3]. Elevated tumor expression ofr B.V. This is an open access article
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.p16(INK4A) (referred to as p16 hereafter), a cyclin-dependent
kinase-4 inhibitor, has been well-characterized in oropharyngeal
cancer patients and is strongly correlated with HPV positivity.
HPV-positivity combined with expression of p16(INK4A) is strong
evidence of biologically relevant infection [4].
Unlike oropharyngeal cancers, an etiologic role of HPV in lar-
yngeal and other malignancies of the head and neck has not been
deﬁnitively established [1,3]. We recently reported the results of a
population-based study to evaluate the genotype-speciﬁc pre-
valence of HPV in invasive laryngeal cancer cases diagnosed in the
U.S. [5]. HPV DNA was detected in 31 of 148 (21%) invasive lar-
yngeal cancers; 13 different genotypes were observed. The
detection of HPV DNA in tumor tissue, however, is not deﬁnitive
evidence for causation. The current report examines p16 expres-
sion in laryngeal cancer cases in order to further elucidate HPV-
related laryngeal cancer development and progression.under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
p16(INK4A) expression and HPV DNA status by histology of invasive laryngeal
tumors.
Histology p16 HPV DNA
No. positive No. negative No. positive No. negative
SCC keratinizing
(n¼49)
3 46 8 41
SCC non-keratinizing 1 16 4 13
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This study was approved by the CDC Institutional Review Board
(IRB) and the IRBs of the University of Hawaii, University of Iowa,
and University of Southern California. All patients were diagnosed
in 1993–2004 within the catchment area of three population-
based cancer registries [5]. Laryngeal cancer cases were selected
from patients with pathologically-conﬁrmed tumors. The majority
of cases were squamous cell carcinomas of all subsites including
the supraglottis, glottis, and subglottis.
De-identiﬁed, clinically annotated formalin-ﬁxed parafﬁn-
embedded (FFPE) tissue specimens were obtained from Residual
Tissue Repositories (RTR) afﬁliated with the National Cancer
Institute's Surveillance, Epidemiology, and End Results (SEER)
Program [6,7]. Through linkage with registry patient and tumor
data, tissue specimens were annotated with de-identiﬁed demo-
graphic, clinical, pathologic, and survival data. Tissue specimens
had been previously genotyped for HPV at the CDC laboratories as
previously described [5,8] using the Linear Array HPV Genotyping
Test for 37 HPV genotypes (LA, Roche Diagnostics, Indianapolis,
IN). The INNO-LiPA HPV Genotyping Assay (LiPA, Innogenetics,
Gent, Belgium) was also employed for specimens testing negative
for HPV and human beta-globin.
2.1. Histologic subtyping by pathologic review
H&E slides of squamous cell carcinoma cases of unspeciﬁed
subtype, i.e. SCC NOS, were reviewed by a study pathologist (M.R.)
for subtype assignment. SCC cases were classiﬁed as keratinizing,
non-keratinizing, basaloid, verrucous, papillary, and spindle cell.
2.2. p16 immunohistochemistry and pathologic review
p16 expression was evaluated via immunohistochemistry.
Sections of tumor tissue were obtained from the same FFPE blocks
previously used for HPV genotyping. A p16 mouse monoclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) (dilution
1:400) was used according to the manufacturer's speciﬁcations.
Slides were read by a study pathologist (M.R.) who was blinded to
the HPV status of cases. p16 staining was evaluated based level of
staining intensity (mild/weak, moderate, strong), intracellular
localization (nuclear, cytoplasmic), staining distribution (patchy,
focal, diffuse), and the proportion of tumor cells stained. Speci-
mens exhibiting strong, diffuse nuclear and cytoplasmic staining
in Z70% of tumor cells were considered to be deﬁnitively positive
for p16 based on established criteria [9,10].
2.3. Statistical analyses
Statistical analyses were conducted using SAS version 9.2.
Comparison of p16 expression used the Chi-square statistic. Sur-
vival was calculated based on the time period from date of diag-
nosis to date of death or date of last follow-up. Overall ﬁve-year
survival by p16 and HPV DNA status was evaluated using the
Kaplan–Meier method and the log-rank test. All tests were two-
sided and a p value o0.05 was considered to be statistically
signiﬁcant.(n¼17)
SCC papillary (n¼9) 1 8 2 7
SCC basaloid (n¼3) 2 1 0 3
SCC spindle cell
(n¼2)
0 2 0 2
SCC verrucous (n¼1) 0 1 1 0
SCC NOS (n¼19) 1 18 1 18
Small cell carcinoma
NOS (n¼1)
0 1 0 1
Total 8 93 16 853. Results
The laryngeal cancer study population has been previously
detailed [5]. Tumor tissue specimens from 101 of 148 cases from
the prior analysis with sufﬁcient tissue for immunohistochemistry
were included in the present study. SCC subtypes included 49
(48.5%) keratinizing, 17 (16.8%) non-keratinizing, 9 (8.9%) papillary,3 (3%) basaloid, 2 (2.0%) spindle cell, and 1 (1.0%) verrucous. A total
of 19 (18.8%) of cases remained classiﬁed as unspeciﬁed SCC and
1 case was a small cell carcinoma.
Eight of the 101 (7.9%) of laryngeal tumors were considered to
be positive for p16 based on the criteria of strong, diffuse p16
staining of the nucleus and cytoplasm in Z70% of tumor cells.
Thirty-two cases which exhibited strong, diffuse nuclear and
cytoplasmic staining in fewer than 70% of tumor cells and were
not considered to be p16 positive. Table 1 compares p16 and HPV
DNA status by histologic subtype. Basaloid SCC tumors exhibited
the largest proportion of p16 positive tumors (2 of 3). All 3 basa-
loid tumors were HPV DNA negative. HPV positivity was highest in
non-keratinizing (4 of 17) and papillary (2 of 9) SCC tumors. Only
2 of the 26 non-keratinizing and papillary SCC cases were positive
for p16 expression.
In total, p16 expression was observed in 2 of 16 (12.5%) HPV
DNA positive laryngeal cancer cases (Table 2). One p16-positive
case was a non-keratinizing SCC positive for HPV 18 (Fig. 1). The
second p16 positive case was a papillary SCC positive for both HPV
35 and 89. Both p16/HPV DNA positive cases were localized
tumors of the glottis diagnosed in males under age 50. The 14 HPV
positive laryngeal cancer cases without p16 expression included
glottal and supraglottal tumors of all stages diagnosed in males
and females primarily aged 50 and older. Overall survival was
evaluated in the 95 cases with vital status and follow-up infor-
mation. p16 was not associated with 5-year survival when mea-
sured based on p16 expression alone (log-rank p value¼0.84) or
positivity for either p16 and/or HPV DNA (log-rank p value¼0.55)
(Fig. 2).4. Conclusions
Our ﬁndings support a limited role of HPV in laryngeal carci-
nogenesis. Fewer than 10% of all laryngeal tumors expressed p16
and p16 expression did not strongly correlate with HPV DNA sta-
tus. In total, only a fraction (2%) of laryngeal cancers were positive
for both p16 and HPV DNA. We previously observed HPV DNA in
over 1 in 5 invasive laryngeal cancers. However, detection of HPV
DNA alone is not indicative of a clinically relevant infection. In
HPV-induced carcinogenesis, the E7 oncoprotein binds and inac-
tivates the retinoblastoma tumor suppressor gene product, pRb
[11]. As pRb is a negative regulator of p16, its inactivation results in
overexpression of p16 [11]. Therefore, HPV-positivity combined
with p16 expression is strong evidence of biologically relevant
infection [4]. Our ﬁndings of limited correlation of p16 with HPV
DNA status contrasts with the few studies that have examined
Table 2
p16(INK4A) expression in HPV-positive invasive laryngeal tumors.
p16 HPV DNA genotype Subsite SEER stage Histology Grade Gender Age group
Positive 18 Glottis Localized SCC non-keratinizing 2 Male 40–49
Positive 35, 89 Glottis Localized SCC papillary 1 Male 40–49
Negative 16 Supraglottis Regional SCC non-keratinizing 2 Female 80–89
Negative 35 Glottis Localized SCC papillary 1 Female 70–79
Negative 39 Supraglottis Regional SCC keratinizing 2 Female 50–59
Negative 16, 54 Supraglottis Regional SCC keratinizing 3 Male 70–74
Negative 18, 33 Glottis Distant SCC keratinizing 2 Male 65–69
Negative 16 Supraglottis Localized SCC keratinizing 2 Male 65–69
Negative 11 Supraglottis Distant SCC NOS 3 Female 55–59
Negative Untyped Glottis Localized SCC verrucous a Male 65–69
Negative 16 Supraglottis Regional SCC keratinizing 3 Male 70–74
Negative 33 Supraglottis Regional SCC keratinizing 2 Female 55–59
Negative 16, 31, 33 Glottis Localized SCC keratinizing 2 Male 45–49
Negative 51 Supraglottis Regional SCC non-keratinizing 3 Male 75–79
Negative 51 Glottis Localized SCC keratinizing 2 Male 60–64
Negative 6 Glottis Regional SCC non-keratinizing 2 Female 50–54
a Tumor grade could not be ascertained based on the registry data and secondary pathologic review.
Fig. 1. p16 expression in invasive laryngeal (glottal) non-keratinizing SCC tumor
positive for HPV 18 DNA. p16 exhibits strong nuclear and cytoplasmic staining of a
diffuse pattern in greater than 70% of tumor cells (20 ).
Fig. 2. p16 expression & HPV DNA status and overall 5-year survival in invasive
laryngeal cancer (n¼95). There was no difference in overall 5-year survival by
positivity for p16 and/or HPV DNA (log-rank p value 0.55).
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a single U.S. institution, 65% of p16 positive cases were also posi-
tive for HPV DNA [12]. In a pooled analysis of data from twostudies, p16 expression was found in 86% of HPV-positive lar-
yngeal cancers [13]. The predominant pattern of p16 expression of
laryngeal cancers that we observed was diffuse, strong expression
in both the nucleus and cytoplasm. However, for the majority of
these cases, fewer than 70% of tumor cells were positive. Wide
variation in p16 staining patterns has been observed in head and
neck cancers [14]. In general, strong, diffuse nuclear and cyto-
plasmic staining in the majority (i.e., Z70%) of tumor cells is
considered to be deﬁnitively positive for p16 [9,10]. This p16
expression pattern is seen in the majority of oropharyngeal can-
cers for which p16 is highly correlated with HPV DNA detection
[9,10,15]. p16 positivity in the absence of HPV DNA—as observed in
a subset of our cases—is consistent with the suggestion that p16
upregulation in laryngeal carcinogenesis may reﬂect somatic
chromosomal alterations unrelated to HPV [16–18].
Although the sample size was limited, we observed some his-
tologic differences by p16 and HPV status. p16 positivity was most
frequently found in basaloid SCC tumors, while HPV DNA positivity
was highest in non-keratinizing and papillary SCC tumors. Inter-
estingly, non-keratinizing SCC and, to a lesser extent, basaloid and
papillary SCC tumors, are the histologic variants that are most
common in HPV-associated oral and oropharyngeal squamous cell
carcinomas [19].
The etiologic and prognostic role of HPV in oropharyngeal
cancers is well-established [1–3]. HPV tumor positivity favorably
inﬂuences outcome, including overall survival, disease-free survi-
val, and recurrence [20–36]. Unlike oropharyngeal cancers, our
ﬁndings do not support a prognostic role of HPV in laryngeal
cancer. This was consistent for p16 alone and in combination with
HPV DNA. We previously observed no survival advantage in HPV
DNA-positive laryngeal cancers [5]. Our ﬁndings are in agreement
with single institution studies that did not observe statistically
signiﬁcant associations of p16 overexpression with laryngeal
cancer survival [12,37,38].
Our ﬁndings support the evidence to date which collectively
suggests that, in contrast with the well-established etiologic and
prognostic role of HPV in oropharyngeal malignancies, its role in
laryngeal cancers is comparatively limited [17]. A major limitation
of our study is the lack of information on tobacco and alcohol use,
which are the predominant risk factors for laryngeal cancers.
Presumably, the majority of laryngeal cancers in the present study
were linked to these exposures. Our study ﬁndings indicate that
any etiologic role of HPV is limited to only a fraction of laryngeal
cancers.
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